drugset / Trial / NCT07082439
Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma
Phase 2
Recruiting
27 enrolled
Abramson Cancer Center at Penn Medicine
Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety and effectiveness of the combination of pembrolizumab and odetiglucan in patients with metastatic colorectal cancer that is predominantly in the liver.
Timeline
- Start
- 2025-09-10
- Primary completion
- 2027-09
- Completion
- 2029-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Odetiglucan | Other / unclassified | 4 mg/kg | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |